The causal impact of ART on NCDs: leveraging quasi-experiments
We applaud the recent editorial in The Lancet Diabetes & Endocrinology, which highlights the challenges of building health systems to provide effective chronic care for both HIV and noncommunicable diseases (NCDs) in sub-Saharan Africa. 1 We agree that "the lynchpin of a successful effort to grow health systems that can deal with communicable diseases and NCDs equally effectively is research." 1 In our opinion, one major focus of such research needs to be the causal impact of antiretroviral therapy (ART) on NCD incidence.
The ART scale-up in sub-Saharan Africa has been one of the most expansive global health efforts for treatment of a single disease to date. In part because of the large gains in life expectancy due to ART, 2 a growing cohort of aging adults on longterm ART has emerged, 3 and a large burden of NCDs may be unmasked. 4 Evidence from numerous studies points to a higher prevalence of NCDs in HIV-positive populations on ART. 5, 6 However, the causal impact of ART on the incidence of major NCDs remains unknown.
Eff orts to ascertain the causal impact of ART on NCD incidence in sub-Saharan Africa have been hindered by several factors. First, few randomised controlled trials or large cohort studies collect data on both ART use and NCD outcomes. Those that do have been conducted in populations where the HIV epidemic is concentrated in high-risk groups, such as men who have sex with men and intravenous drug users, which differ from the general population in important risk factors. Second, eff orts to accurately disentangle the complex relationships between HIV infection, ART use, and NCD incidence require well powered, long-term studies that inevitably demand large investments of time and funding. Lastly, the eff ect of ART on NCD incidence is likely to vary with the types of ART regimens used, which in turn vary widely across world regions.
A particularly promising path to fi lling the knowledge gap on the causal impact of ART on NCDs are quasiexperiments-such as regression discontinuity and difference-indiff erences studies-done in the large linked population-based and clinical cohorts that are often available in health and demographic surveillance systems. Quasi-experimental studies use as-good-as random assignments of treatments, generated by policy decisions, the practice of medicine, or chance events in nature-leading to internally valid causal estimates. At the same time, these studies do not interfere with the real-world delivery of ART, ensuring high external validity of fi ndings. An additional advantage of population-based studies is that they can establish spillover effects from patients taking ART to others. In HIV hyperendemic communities, such effects are likely to contribute substantially to an ART-induced epidemiological transition, because communities in which HIV-positive members can lead productive lives into old age face diff erent human and economic development prospects than communities with high HIV mortality.
Real-world causal impact data linking ART and NCDs will provide a critical evidential basis for some of the most pressing health policy questions in countries with large ART programmes: should ART patients be routinely screened for diabetes, hypertension, and depression? Should HIV care be differentiated by comorbidities and therapeutic response? Should vertical ART programmes be integrated into the general health care system? 
The ecological cost of continued use of endocrine-disrupting chemicals
Attina and colleagues 1 recently estimated the economic burden due to the health eff ects of endocrinedisrupting chemicals (EDCs) to be US$340 billion in the USA and $217 billion in Europe. Extrapolating these costs to low-income and middle-income countries, where many of the EDCs the investigators included in their analysis continue to be produced and used widely (eg, polychlorinated biphenyls and organochlorine pesticides), we hypothesise that the costs associated with EDCs are likely to be substantially higher.
Additionally, Attina and colleagues' analysis was focused on health eff ects, so did not take into account the effects of these pervasive exposures on aquatic and terrestrial ecosystems.
With respect to oceans, debris damage costs the Asia-Pacifi c marine industry an estimated $1·26 billion annually, 2 and EDCs are associated with impaired reproduction and development, especially in molluscs and crustaceans. 3 According to the UN Food and Agriculture Organization (FAO), fi sheries and aquaculture support the livelihoods of 10-12% of the world's population and fish accounts for nearly 17% of the global population's protein intake. 4 Continued pollution of aquatic ecosystems, which are already stressed from overfi shing, could have severe economic and nutritional consequences. Furthermore, ruminants are increasingly being exposed to solid waste. Livestock mortality from rumen impaction due to plastic ingestion is resulting in severe production losses in low-income and middle-income countries. 5 The effects of EDCs on livestock reproduction, documented in developed countries, 6 also has important implications for food security and nutrition.
The UN Sustainable Development Goals emphasise the importance of One Health: acknowledging that human health is dependent on animal and environmental health. Future research into the disease burden and costs associated with EDCs should take a similar approach, recognising the indirect eff ects on food security and nutrition through losses in food production. Given that the FAO estimates that the global food supply must increase by an estimated 60% to meet the projected demand by 2050, 7 potential losses resulting from EDCs cannot be ignored.
